Latest in Tomorrow

Image credit: Justin Sullivan via Getty Images

A generic HIV prevention drug should arrive in 2021

Gilead will share its exclusive Truvada patent with Teva.
386 Shares
Share
Tweet
Share
Save

Sponsored Links

Justin Sullivan via Getty Images

Pharmaceutical giant Gilead has agreed to release its exclusive patent to manufacture and sell the HIV-prevention drug Truvada. This means we could see a generic version of the pre-exposure prophylaxis (or PrEP) on the market earlier than expected. The news is seen as a win for individuals who may be at a greater risk of contracting HIV.

The announcement, buried in Gilead's 2019 Q1 SEC filing, grants Teva as the sole generic manufacturer in the US. But Gilead will retain its exclusive rights for another 15 months. "We don't expect generic Truvada in the United States until 2021," the company said in its earnings call.

#BreakThePatent, a group that has advocated for a generic version, says sharing the patent with Teva alone won't do enough to reduce the drug's price. According to #BreakThePatent, Gilead currently prices Truvada at between $1,600 and $2,000 for a month's supply. The group is also concerned with the lack of transparency around the settlement.

According to a study published by the National Institutes of Health, Truvada can reduce the risk of contracting HIV by 99 percent, but initially, the drug wasn't as popular as many hoped it would be. A few years ago, in an effort to boost adoption, the drug delivery company Nurx began delivering Truvada right to people's doorsteps. Advocates hope that lower cost, generic versions of the pill might reach more people.

All products recommended by Engadget are selected by our editorial team, independent of our parent company. Some of our stories include affiliate links. If you buy something through one of these links, we may earn an affiliate commission.
Comment
Comments
Share
386 Shares
Share
Tweet
Share
Save

Popular on Engadget

NASA hopes OSIRIS-REx data will explain an asteroid's mini-eruptions

NASA hopes OSIRIS-REx data will explain an asteroid's mini-eruptions

View
'Chilling Adventures of Sabrina' season 3 arrives January 24th

'Chilling Adventures of Sabrina' season 3 arrives January 24th

View
Apple may offer tighter iOS parental controls this week

Apple may offer tighter iOS parental controls this week

View
Bethesda stops work on 'The Elder Scrolls: Legends'

Bethesda stops work on 'The Elder Scrolls: Legends'

View
Apple TV+ scores its first award nomination with 'The Morning Show'

Apple TV+ scores its first award nomination with 'The Morning Show'

View

From around the web

Page 1Page 1ear iconeye iconFill 23text filevr